Clinical trials: Cerebrovascular Disorder
Fabry Disease
Post Trial Access to Lucerastat for Patients With Fabry Disease Who Participated in Study ID-069A302
This is a Post Trial Access program for patients with Fabry Disease who previously participated in the ID-069A302 (MODIFY OLE) trial and who were still enrolled in the study at the time the Sponsor decided to discontinue…
- Trial name
- NCT07762638
- Testing
- Lucerastat
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Intracranial Hemorrhages, Traumatic Brain Injury
Evaluate the SENSE Device's Ability to Monitor and Detect Intracranial Hemorrhage
This study is a two-stage, pivotal, prospective, non-randomized, multi-center, within patient comparison of the SENSE device and the standard diagnostic test, head CT scan in patients with a diagnosis of primary spontaneous ICH…
- Trial name
- NCT04642443
- Testing
- SENSE Device
- Where
- United States
- Volunteers
- 450 people
- Sponsor
- Sense Diagnostics, LLC
Apoplexy; Stroke, Spinal Cord Injuries
Clinical Trial ROBERT® - Project Active Training
The overall purpose with this clinical trial is to, monitor and secure ROBERT®'s clinical performance and safety in a clinical environment in the regional hospital North Denmark, Neuro Unit North.
- Conditions
- Apoplexy; Stroke, Spinal Cord Injuries, Safety, Usability
- Trial name
- NCT04304976
- Testing
- ROBERT®
- Where
- Denmark
- Volunteers
- 8 people
- Sponsor
- Lifescience-Robotics
Coronary Artery Disease, Cerebrovascular Disease
RESTORE-IT-Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients With a History of Atherosclerotic Disease
The objective of this study is to evaluate an antibiotic therapy called Rifalazil to determine its effect on hardening of the carotid arteries.
- Conditions
- Coronary Artery Disease, Cerebrovascular Disease, Peripheral Vascular Disease
- Trial name
- NCT00385385
- Testing
- Rifalazil
- Where
- 6 sites in United States, Canada
- Volunteers
- 72 people
- Sponsor
- ActivBiotics
Fabry Disease
Extension Study of PRX-102 for up to 60 Months
To evaluate the ongoing safety, tolerability, and efficacy parameters of PRX-102 in adult Fabry patients who have successfully completed treatment with PRX-102 in studies PB-102-F01 and PB-102-F02.
- Trial name
- NCT01981720
- Testing
- PRX-102 (pegunigalsidase alfa)
- Where
- 8 sites in United States, Paraguay and 2 more
- Volunteers
- 15 people
- Sponsor
- Protalix
Acute Ischemic Stroke
A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects
This Phase 1 study is planned to establish the clinical safety and pharmacokinetics profile of multiple dose of LT3001 drug product and to investigate drug interactions of LT3001 with potential concomitant medications in healthy…
- Trial name
- NCT04809818
- Testing
- LT3001 drug product, Aspirin, Clopidogrel
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Lumosa Therapeutics Co., Ltd.
Muscle Spasticity, Cerebrovascular Accident
Asian Botulinum Clinical Trial Designed for Early Stroke Spasticity
The aim of this clinical study is to investigate the efficacy and safety of Dysport® in patients with early onset of upper limb spasticity within 2-12 weeks after stroke.
- Trial name
- NCT00234546
- Testing
- Botulinum toxin type A
- Where
- 5 sites in Hong Kong, Malaysia and 3 more
- Volunteers
- 162 people
- Sponsor
- Ipsen
Acute Ischemic Stroke
The Vesalio NeVa Stent Retriever Study for Treatment of Large Vessel Occlusion Strokes: CLEAR Study
A prospective, open label, single-arm 90-day study designed to assess the safety, performance and efficacy of thrombus removal in subjects presenting with acute ischemic stroke with the NeVa stent retrievers.
- Trial name
- NCT04514562
- Testing
- NeVa Stent Retrievers
- Where
- 7 sites in United States
- Volunteers
- 120 people
- Sponsor
- Vesalio
Fabry Disease, Chronic Kidney Disease, Stage IV (Severe)
Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme
This study was designed to determine appropriate treatment with Fabrazyme at a biweekly dose of either 1 mg/kg or 3 mg/kg in a population of patients with severe renal disease burden.
- Trial name
- NCT00837824
- Testing
- Fabrazyme (agalsidase beta)
- Where
- 9 sites in United States
- Volunteers
- 20 people
- Sponsor
- Genzyme, a Sanofi Company
Atrial Fibrillation, Atrial Flutter
Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk
The IMPACT Study will investigate the potential clinical benefit of the combined use of BIOTRONIK Home Monitoring (HM) technology and a predefined anticoagulation plan compared to conventional device evaluation and…
- Conditions
- Atrial Fibrillation, Atrial Flutter, Stroke, Embolism, Systemic Arterial
- Trial name
- IMPACT (NCT00559988)
- Testing
- Home Monitoring Guided OAC, Physician-Directed OAC
- Where
- 80 sites in United States, Australia and 4 more
- Volunteers
- 2,718 people
- Sponsor
- Biotronik, Inc.
Prevention & Control
Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease
The primary objectives of this study are: To determine whether rivaroxaban 2.5 mg twice daily (bid) + aspirin 100 mg once daily (od) compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction…
- Trial name
- COMPASS (NCT01776424)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Aspirin, Pantoprazole
- Where
- 565 sites in United States, Argentina and 31 more
- Volunteers
- 27,395 people
- Sponsor
- Bayer
Carotid Stenosis
[F-18] RGD-K5 Positron Emission Tomography (PET) in Participants With Carotid Artery Stenosis
This trial will be the first trial for the Investigation Product (IP), [F-18]RGD-K5 for carotid plaque imaging and will be conducted as a Phase II trial since this compound has already been tested in humans for phase I and phase…
- Trial name
- NCT01602471
- Testing
- [F-18]RDG-K5
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Siemens Molecular Imaging
Carotid Artery Disease
POST-APPROVAL STUDY of TRANSCAROTID ARTERY REVASCULARIZATION in PATIENTS With SIGNIFICANT CAROTID ARTERY DISEASE
The ROADSTER 2 Study is intended to evaluate real world usage of the ENROUTE Transcarotid Stent when used with the ENROUTE Transcarotid Neuroprotection System by physicians of varying experience with the transcarotid technique.
- Trial name
- NCT02536378
- Where
- 43 sites in United States, Germany and 1 more
- Volunteers
- 692 people
- Sponsor
- Silk Road Medical
Stroke, Surgery
The Neuralert Stroke Monitor Pilot Trial
This trial aims to demonstrate that the Neuralert Monitoring System will detect strokes before they would be identified by current standard of care.
- Trial name
- NCT06368193
- Testing
- Neuralert Monitor
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Neuralert Technologies LLC
Cerebral Infarction
Safety and Efficacy of Clopidogrel for Cerebral Infarction Treatment
The primary objective is to compare the safety of clopidogrel 50mg and 75mg in cerebral infarction with respect to incidence of bleeding adverse events.
- Trial name
- NCT00386191
- Testing
- clopidogrel (SR25990C)
- Where
- Japan
- Volunteers
- 1,110 people
- Sponsor
- Sanofi
Carotid Artery Diseases
Post-approval Study of Transcarotid Artery Revascularization in Standard Risk Patients With Significant Carotid Artery Disease
The study objective is to evaluate real world usage of the ENROUTE Transcarotid Stent when used with the ENROUTE Transcarotid Neuroprotection System in patients at standard risk for adverse events from carotid endarterectomy
- Trial name
- NCT05365490
- Testing
- Transcarotid Artery Revascularization (TCAR)
- Where
- 53 sites in United States
- Volunteers
- 344 people
- Sponsor
- Silk Road Medical
ANCA Associated Vasculitis (AAV)
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe active Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)
- Trial name
- NCT06868290
- Testing
- Rapcabtagene autoleucel, Active Comparator, Glucocorticoids
- Where
- 39 sites in United States, Brazil and 6 more
- Volunteers
- 126 people
- Sponsor
- Novartis Pharmaceuticals
Intracranial Aneurysms
TRAIL: Treatment of Intracranial Aneurysms With LVIS® System
A prospective, multicenter, observational assessment of the safety and effectiveness of the LVIS® device in the treatment of wide necked intracranial aneurysms.
- Trial name
- TRAIL (NCT02921711)
- Testing
- LVIS®
- Volunteers
- 90 people
- Sponsor
- Microvention-Terumo, Inc.
Cerebral Arteriovenous Malformation
Treatment of Cerebral Arteriovenous Malformations With SQUID Liquid Embolic Agent (CHOICE)
The objective of this study is to further establish that SQUID, an alternative liquid embolic agent with specific properties, is a safe and effective alternative in bAVM endovascular treatment strategy available to date.
- Trial name
- CHOICE (NCT03413852)
- Testing
- SQUID non-adhesive liquid embolic agent
- Where
- 19 sites in Belgium, Denmark and 3 more
- Volunteers
- 111 people
- Sponsor
- Embo-Flüssigkeiten A.G.
Intracranial Aneurysm
Efficacy and Safety of the Self-expanding Intracranial Stent (Tonbridge) for Endovascular Treatment of Intracranial Aneurysms
The purpose of this study is to assess the efficacy and safety of Self-expanding Intracranial Stent (Tonbridge), by comparing the data obtained from Self-expanding Intracranial Stent (Zhuhai Tonbridge Medical Tech.
- Trial name
- NCT05755516
- Testing
- Self-expanding Intracranial Stent (Tonbridge), LVIS and LVIS Jr. (MicroVention)
- Where
- 14 sites in China
- Volunteers
- 204 people
- Sponsor
- Ton-Bridge Medical Tech. Co., Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.